Genmab ASGNMSF 93 Days Inventory is 27.38 as of Mar. 2026, which is 27% above its 10-year median of 21.51. GuruFocus rates GNMSF with a GF Score™ of 93/100 and a GF Value™ of $337.53 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Genmab AS ranks better than 94.67% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Genmab AS's Average Total Inventories for the
three
months ended in Mar. 2026 was $20 Mil. Genmab AS's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $65 Mil.
Hence, Genmab AS's Days Inventory for the
three
months ended in Mar. 2026 was 27.38.
The historical rank and industry rank for Genmab AS's Days Inventory or its related term are showing as below:
GNMSF'
s Days Inventory Range Over the Past 10 Years
Min: 21.28 Med: 21.51 Max: 88.48
Current: 22.08
During the past 13 years, Genmab AS's highest Days Inventory was 88.48. The lowest was 21.28. And the median was 21.51.
GNMSF's Days Inventory is ranked better than 94.67% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs GNMSF: 22.08
Genmab AS's Days Inventory
increased
from Mar. 2025 (22.81) to Mar. 2026 (27.38).
It might indicate that Genmab AS's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Genmab AS's Inventory Turnover for the
three
months ended in Mar. 2026 was 3.33.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genmab AS's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.02.
Genmab AS (OTCPK:GNMSF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Genmab AS's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genmab AS's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Genmab AS Days Inventory Related Terms
Genmab AS Days Inventory Historical Data
* Premium members only.
The historical data trend for Genmab AS's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNMSF vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Genmab AS's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Days Inventory distribution charts can be found below:
* The bar in red indicates where Genmab AS's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (GNMSF) has a Days Inventory of 27.38 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genmab AS and its competitors. This is 27% above median its historical median of 21.51. Over the past decade, Genmab AS's Days Inventory has ranged from 21.28 to 88.48. According to the industry distribution chart, Genmab AS ranks #34 out of 638 companies in the Biotechnology industry, placing it in the top 5.3%.
Is Genmab AS's Days Inventory too high?
Genmab AS's current Days Inventory of 27.38 is 27% above median its 10-year median of 21.51. Over the past 10 years, this metric has ranged from a low of 21.28 to a high of 88.48. The Biotechnology industry median Days Inventory is 183.88. Genmab AS's value of 27.38 is 85.1% below this industry median. Based on the distribution chart, Genmab AS ranks #34 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #34 out of 638 companies for Days Inventory. This places Genmab AS in the top 5% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.88. Genmab AS's value of 27.38 is 85.1% below this benchmark. Historically, Genmab AS's own Days Inventory has ranged from 21.28 to 88.48 over the past decade. While the company's 10-year median is 21.51 vs. the industry median of 183.88, Genmab AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Days Inventory of 27.38 is 85.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Days Inventory is 27.38, which is 27% above median its own 10-year median of 21.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $337.53, compared to a current price of $275.00 — trading 18.5% below its estimated fair value. The current Days Inventory is 27.38, which is 27% above median its 10-year median of 21.51 and 85.1% below the Biotechnology industry median of 183.88. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Days Inventory is 27.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GNMSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $275.00 is trading 18.5% below its estimated GF Value™ of $337.53.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for GNMSF:
Days Inventory: 27.38 (27% above median its 10-year median of 21.51)
GF Value™: $337.53 vs. price of $275.00 (18.5% below fair value)
Industry Position: 85.1% below the Biotechnology median (#34 of 638)
No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score
Get the complete analysis for GNMSF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNMSF has been successfully added to your 
